Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1657 1658 1674 1678 1682
This examiner grants 49% of resolved cases
Fernando NMN Ivich serves in Tech Center 1600 and Art Unit 1600. He has handled 39 resolved cases to date. His allowance rate is 48.7 percent, which indicates that more than half of the cases in this docket do not result in a grant. This 48.7 percent rate suggests a challenging environment where applicants must be diligent in their technical arguments to secure a patent.
The interview lift for this examiner is 69.8 percent. This 69.8 percent lift is exceptionally high, suggesting that interviews are a critical component of a successful prosecution strategy. Engaging in a direct dialogue appears to be the most effective way to bridge the gap between a rejection and an allowance, potentially increasing the chances of success compared to the 48.7 percent baseline.
The median days to allowance is 1469. This 1469 day period reflects a lengthy prosecution cycle for successful applications. Applicants should be prepared for a duration of 1469 days when seeking a patent through this examiner, factoring this long pendency into their overall intellectual property management strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19281154 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | Non-Final OA | Janssen Biotech, Inc. |
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | Non-Final OA | QUEST DIAGNOSTICS INVESTMENTS LLC |
| 18442934 | COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17997878 | DETECTION ASSAY FOR ANTI-SARS-COV-2 ANTIBODIES | Non-Final OA | The Regents of the University of California |
| 17293678 | MOLECULES AND METHODS FOR IMPROVED IMMUNODETECTION OF SMALL MOLECULES SUCH AS HISTAMINE | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 17618869 | TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 17619958 | IMMUNE CELL SIGNATURE FOR BACTERIAL SEPSIS | Non-Final OA | The General Hospital Corporation |
| 17266029 | METHOD FOR CULTURING CANCER TISSUE OR TISSUE ANALOGOUS TO CANCER TISSUE | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18413325 | SYSTEM AND METHOD FOR DETECTING DELETERIOUS MICROBIAL ACTIVITY IN HYDROGEN RESERVOIRS | Final Rejection | Battelle Memorial Institute |
| 17265718 | TEST TO ASSESS LIVER DISEASE SEVERITY | Final Rejection | University of Cincinnati |
| 17488649 | SPR-BASED BINDING ASSAY FOR THE FUNCTIONAL ANALYSIS OF MULTIVALENT MOLECULES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18104055 | NPERSEVERE: BIOMARKERS ESTIMATING BASELINE MORTALITY RISK FOR NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS | Non-Final OA | Children's Hospital Medical Center |
| 18383393 | METHODS OF IMPROVING NEURODEGENERATIVE DISORDERS BY TARGETED DELIVERY OF THERAPEUTIC AGENTS | Final Rejection | West Virginia University Board of Governors on behalf of West Virginia University |
| 17637098 | SCALED-UP METHODS FOR PURIFYING ANTIBODIES | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | Final Rejection | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18747407 | ULTRA-BRIGHT NANOPARTICLE FLUORESCENT DYE COMPLEXES | Non-Final OA | CYTEK BIOSCIENCES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy